Antibody

1,032개 · ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved1,032 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

AntibodyCurated CorestaleJanssenApproved

Remicade® (Remicade®)

Crohn's Disease · Ankylosing Spondylitis

#AnkylosingSpondylitis#Antibody#Approved#BioJungboMoa-pick#Popular+3
Trials 406Status Active
AntibodyCurated CorestaleRochePhase 3

Pertuzumab (Pertuzumab)

Colorectal Cancer · HER2

#HER2#Antibody#Phase3#BioJungboMoa-pick#Popular+3
Trials 233Status Discontinued
AntibodyLimited DatastaleMerckPhase 2

pembrolizumab (KEYTRUDA®, KEYTRUDA® (pembrolizumab))

Solid Tumors · Solid Tumor, Adult

#SolidTumorAdult#Antibody#Phase2#Popular#monoclonal-antibody+3
Trials 212Status Recruiting
AntibodyCurated CorestaleAstraZenecaPhase 3

Tremelimumab (Tremelimumab)

Hepatocellular Carcinoma · Muscle Invasive Bladder Cancer

#MuscleInvasiveBladderCancer#Antibody#Phase3#BioJungboMoa-pick#Popular+4
Trials 195Status Recruiting
AntibodyLimited DatastaleAstraZenecaPhase 2

durvalumab + tremelimumab (STRIDE, STRIDE (durvalumab + tremelimumab))

Advanced Unresectable Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#Popular#monoclonal-antibody+3
Trials 185Status Recruiting
AntibodyLimited DatastaleMerckPhase 2

pembrolizumab or nivolumab (The combination of radiotherapy with anti-PD1, The combination of radiotherapy with anti-PD1 (pembrolizumab or nivolumab))

Melanoma · Melanoma

#Melanoma#Antibody#Phase2#Popular#monoclonal-antibody+1
Trials 185Status Active
AntibodyLimited DatastaleBeiGenePhase 1

BGB-A317 (Tislelizumab, Tislelizumab (BGB-A317))

Advanced Solid Tumor · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase1#Popular#monoclonal-antibody+2
Trials 184Status Recruiting
AntibodyLimited DatastaleRochePhase 1

HERCEPTIN (MAB HER 2, MAB HER 2 (HERCEPTIN))

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase1#Popular#monoclonal-antibody+2
Trials 183Status Recruiting
AntibodyCurated CorestaleRocheApproved

Tocilizumab (Tocilizumab)

Multiple Myeloma (MM); Multiple Myeloma Refractory · Chronic Lymphocytic Leukemia

#ChronicLymphocyticLeukemia#Antibody#Approved#BioJungboMoa-pick#Popular+5
Trials 161Status Recruiting
AntibodyLimited DatastaleXin-Hua XuPhase 2

AK104 (Cadonilimab, Cadonilimab (AK104))

Non-small Cell Lung Cancer · Leptomeningeal Metastasis

#LeptomeningealMetastasis#Antibody#Phase2#Popular#monoclonal-antibody+3
Trials 155Status Recruiting
AntibodyCurated CorestaleRochePhase 3

Obinutuzumab (Obinutuzumab)

Breast Adenocarcinoma; Metastatic Breast Carcinoma · B-cell Lymphoma

#B-cellLymphoma#Antibody#Phase3#BioJungboMoa-pick#Popular+5
Trials 153Status Recruiting
AntibodyLimited DatastaleInnoventPhase 3

Sintilimab (Sintilimab)

Advanced Hepatocellular Carcinoma (HCC) · HER2

#HER2#Antibody#Phase3#Popular#monoclonal-antibody+2
Trials 152Status Recruiting
AntibodyLimited DatastaleNovartisPhase 3

secukinumab (AIN457, AIN457 (secukinumab))

Asthma · Psoriatic Arthritis

#PsoriaticArthritis#Antibody#Phase3#Popular#monoclonal-antibody+2
Trials 148Status Active
AntibodyCurated CorestaleJunshi BiosciencesPhase 3

Toripalimab (Toripalimab)

Metastatic Colorectal Cancer; Liver Metastases · Gastric Cancer

#GastricCancer#Antibody#Phase3#BioJungboMoa-pick#Popular+5
Trials 145Status Recruiting
AntibodyLimited DatastaleRochePhase 3

atezolizumab (Tecentriq, MPDL3280A, Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody)

Triple-Negative Breast Cancer · Colorectal Cancer

#ColorectalCancer#Antibody#Phase3#Popular#monoclonal-antibody+2
Trials 143Status Active
AntibodyLimited DatastalePENG YUANPhase 2

QL1706 (Iparomlimab and Tuvonralimab, Iparomlimab and Tuvonralimab (QL1706))

Platinum Resistant Ovarian Cancer; Platinum Refractory Epithelial Ovarian Cancer · Gastric Cancer (GC)

#GastricCancerGC#Antibody#Phase2#Popular#monoclonal-antibody+4
Trials 143Status Recruiting
AntibodyLimited DatastaleRochePhase 3

atezolizumab (Tecentriq, MPDL3280A, Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody)

Carcinoma, Non-Squamous Non-Small Cell Lung · PD-L1

#PD-L1#Antibody#Phase3#Popular#monoclonal-antibody+3
Trials 141Status Active
AntibodyLimited DatastaleMerck KGaAPhase 3

Avelumab (Avelumab)

Non Small Cell Lung Cancer; Colorectal Cancer · Locally Advanced or Metastatic Urothelia

#LocallyAdvancedorMetastaticUroth#Antibody#Phase3#Popular#monoclonal-antibody+4
Trials 138Status Active
AntibodyLimited DatastaleRochePhase 3

Mabthera (Mabthera)

Relapsed Diffuse Large B-cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma · FRα

#FR#Antibody#Phase3#Popular#monoclonal-antibody+4
Trials 129Status Active
AntibodyLimited DatastaleJiangsu HengruiPhase 2

Camrelizumab (Camrelizumab)

Advanced Hepatocellular Carcinoma (HCC) · HER2

#HER2#Antibody#Phase2#Popular#monoclonal-antibody+3
Trials 127Status Recruiting

3 / 52 pages

← PreviousNext →